Pliant Therapeutics (PLRX) Competitors $1.62 +0.03 (+1.89%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.02 (+1.54%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. ZYBT, SANA, SNDL, ERAS, ORKA, ORIC, CKPT, TECX, RGNX, and OLMAShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Zhengye Biotechnology (ZYBT), Sana Biotechnology (SANA), SNDL (SNDL), Erasca (ERAS), Oruka Therapeutics (ORKA), ORIC Pharmaceuticals (ORIC), Checkpoint Therapeutics (CKPT), Tectonic Therapeutic (TECX), REGENXBIO (RGNX), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Zhengye Biotechnology Sana Biotechnology SNDL Erasca Oruka Therapeutics ORIC Pharmaceuticals Checkpoint Therapeutics Tectonic Therapeutic REGENXBIO Olema Pharmaceuticals Pliant Therapeutics (NASDAQ:PLRX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Does the MarketBeat Community favor PLRX or ZYBT? Pliant Therapeutics received 76 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7663.87% Underperform Votes4336.13% Zhengye BiotechnologyN/AN/A Is PLRX or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Zhengye Biotechnology N/A N/A N/A Do insiders and institutionals hold more shares of PLRX or ZYBT? 97.3% of Pliant Therapeutics shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to PLRX or ZYBT? In the previous week, Pliant Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 9 mentions for Pliant Therapeutics and 7 mentions for Zhengye Biotechnology. Pliant Therapeutics' average media sentiment score of 1.04 beat Zhengye Biotechnology's score of 0.27 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, PLRX or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M61.58-$161.34M-$3.47-0.46Zhengye Biotechnology$189.75M2.54N/AN/AN/A Do analysts recommend PLRX or ZYBT? Pliant Therapeutics presently has a consensus target price of $13.31, suggesting a potential upside of 739.91%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPliant Therapeutics beats Zhengye Biotechnology on 8 of the 11 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.30M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.477.3822.6318.55Price / Sales61.58241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book0.206.476.704.25Net Income-$161.34M$143.68M$3.23B$248.27M7 Day Performance0.96%1.85%1.36%1.28%1 Month Performance15.69%6.73%3.85%3.75%1 Year Performance-87.48%-2.72%15.87%5.31% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.305 of 5 stars$1.62+1.9%$13.31+721.8%-86.5%$99.45M$1.58M-0.4990Upcoming EarningsNews CoveragePositive NewsZYBTZhengye BiotechnologyN/A$7.70-23.5%N/AN/A$363.18M$189.75M0.00278High Trading VolumeSANASana Biotechnology1.9079 of 5 stars$1.59-3.6%$10.80+579.2%-78.9%$357.79MN/A-1.14380Upcoming EarningsSNDLSNDL3.0529 of 5 stars$1.36-2.9%$3.63+166.5%-39.7%$357.38M$920.45M-4.39580ERASErasca2.9702 of 5 stars$1.24+6.9%$4.83+289.8%-27.4%$351.25MN/A-1.49120Analyst ForecastORKAOruka Therapeutics3.156 of 5 stars$9.30+0.9%$39.86+328.6%N/A$348.20MN/A-1.49N/AAnalyst RevisionNews CoveragePositive NewsGap UpORICORIC Pharmaceuticals3.9858 of 5 stars$4.87+2.1%$18.86+287.2%-35.3%$345.90MN/A-2.6880Upcoming EarningsNews CoverageCKPTCheckpoint Therapeutics2.4019 of 5 stars$4.04flat$4.33+7.3%+195.7%$338.41M$41,000.00-2.2010TECXTectonic Therapeutic2.5479 of 5 stars$17.92+5.3%$72.40+304.0%N/A$334.44MN/A-3.04120Upcoming EarningsShort Interest ↑RGNXREGENXBIO4.4729 of 5 stars$6.67+12.3%$31.63+374.1%-37.4%$334.28M$83.33M-1.33370Upcoming EarningsNews CoveragePositive NewsOLMAOlema Pharmaceuticals2.4724 of 5 stars$4.75+7.5%$27.67+482.5%-49.3%$324.58MN/A-2.1770Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies ZYBT Alternatives SANA Alternatives SNDL Alternatives ERAS Alternatives ORKA Alternatives ORIC Alternatives CKPT Alternatives TECX Alternatives RGNX Alternatives OLMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRX Stock Free PLRX Stock Alerts